Clinical Trials Logo

Disease Progression clinical trials

View clinical trials related to Disease Progression.

Filter by:

NCT ID: NCT06331416 Not yet recruiting - COPD Clinical Trials

One-device Multiparametric Home Telemonitoring of Patients With Chronic Obstructive Pulmonary Disease Exacerbation

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Chronic obstructive pulmonary disease (COPD) exacerbations are risk factors for disease progression and short-term re- hospitalizations. We propose a randomized controlled trial to evaluate the efficacy of a one-device multiparameter telemonitoring in reducing functional decline, symptoms, and risk of re-hospitalization of patients discharged after hospitalization for exacerbated COPD.

NCT ID: NCT06306170 Recruiting - Gynecologic Cancer Clinical Trials

Advanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART)

GYN-ART
Start date: February 15, 2024
Phase:
Study type: Observational

This is an observational mono-institutional study. Patients with gynecologic tumors treated with advanced radiotherapy- Image Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Body Radiotherapy (SBRT)- will be included and toxicity and outcomes analyzed.

NCT ID: NCT06302959 Not yet recruiting - Clinical trials for Severe Eosinophilic Asthma

Clock Proteins as a Prognostic Marker for Disease Progression

CLOCK-PM
Start date: May 1, 2024
Phase:
Study type: Observational

Asthma is a chronic inflammatory disease of the airways that follows a strong circadian rhythm: Signs of inflammation and symptoms worsen especially in the early morning hours. The molecular circadian clock, which is a complex machinery of transcriptional and translational feedback loops, seems to reflect the inflammatory environment of peripheral blood leukocytes. Therefore, in this observational study we will monitor the molecular circadian clock in patients with severe eosinophilic asthma before and during mepolizumab treatment. Our major goal is to evaluate the potential of the molecular circadian clock to serve as a prognostic marker for disease progression, treatment response or remission in patients with severe eosinophilic asthma. The molecular circadian clock will be monitored in blood and sputum leukocytes from patients with severe eosinophilic asthma before mepolizumab treatment, after 4 month of mepolizumab therapy, and once they reach remission under mepolizumab treatment. Effects will be compared to healthy controls and patients with mild-moderate asthma without mepolizumab treatment.

NCT ID: NCT06292897 Recruiting - Obesity Clinical Trials

Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression

OBESITA'&PCa
Start date: March 20, 2023
Phase:
Study type: Observational

Evaluate the protein expression of lactate dehydrogenase enzyme (LDHA) and MCT-1/-4 transporters, involved in lactate synthesis and transport, in prostate carcinoma tissues from severely overweight/obese (BMI > 27.5) and non-severely overweight/normoweight (BMI < 27.5) patients affected by prostate carcinoma. ii. Characterize the immune infiltrate in the prostate carcinoma of the aforementioned patients. iii. Assess the association between intra-tumoral lactate accumulation (using LDHA and MCT-4 protein expression levels as readouts) and alterations in the tumor immune microenvironment and/or deregulation of relevant oncogenic pathways.

NCT ID: NCT06278428 Recruiting - Child Development Clinical Trials

Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age

Start date: November 1, 2023
Phase:
Study type: Observational [Patient Registry]

According to estimates by the World Health Organization in 2019, more than 50 million people around the world have epilepsy. Nearly 80% of patients with epilepsy live in developing countries. Among them, children under 2 years old are the group with the highest incidence of epilepsy, and at the same time, the most dangerous epilepsy groups are also likely to start at these ages. World medical literature on epileptic encephalopathy and early-onset development before 2 years of age records that 71% of children have severe intellectual disability and 60% of children show signs of autism spectrum disorder, of which Children with epileptic and developmental encephalopathy due to genetic causes are at higher risk of developing neurodevelopmental disorders than children with epileptic and developmental encephalopathy due to other causes. However, in Vietnam, there is no research on this topic. The question is what are the phenotypes, genotypes, and progression after 2 years of follow-up of Vietnamese children with epileptic and developmental encephalopathy with onset before 2 years of age?

NCT ID: NCT06267781 Recruiting - Multiple Sclerosis Clinical Trials

RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies

TRANSPLANTPRO
Start date: September 2, 2022
Phase:
Study type: Observational

To study whether highly effective therapies can halt disease progression in people with multiple sclerosis by modulating the peripheral myeloid landscape.

NCT ID: NCT06265454 Not yet recruiting - Myopia Progression Clinical Trials

Low Dose Atropine Eye Drops in Myopic Egyptian Children

LAMP
Start date: September 1, 2024
Phase: Phase 2
Study type: Interventional

Previous Studies reported that low concentration atropine eye drops may be effective in increasing the choroidal blood flow and thickness and this slows myopia progression. purpose of the study is to compare changes in axial length, anterior chamber depth, choroidal thickness, central corneal thickness and anterior scleral thickness among myopic children receiving atropine 0.05% or 0.01% and placebo.

NCT ID: NCT06248138 Not yet recruiting - Coronary Stenosis Clinical Trials

Factors Related to the Progression of Non-target Coronary Lesions

Start date: February 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to learn about correlation between traditional risk factors and emerging risk factors on the progression of non-target coronary lesions in patients with non-target lesions on at least two coronary angiographies at the First Affiliated Hospital of Shandong First Medical University. The main question it aims to answer is what the correlation between emerging risk factors and progression of coronary non-target lesions, and try to explore the powerful predictors of progression of coronary non-target lesions and cardiovascular events. Participants will be divided into two groups based on coronary angiography results: 1. progress group:There is at least one major coronary artery (left main artery, left anterior descending artery, left circumflex artery or the right coronary artery) had non-target lesions, and the coronary artery stenosis rate reached the progressive level on follow-up angiography. 2. Non-progress groups: On repeat angiography, the rate of coronary stenosis did not reach progressive levels.

NCT ID: NCT06235853 Completed - Bladder Cancer Clinical Trials

Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer

Start date: January 1, 2020
Phase:
Study type: Observational

Bladder cancer (BC) is one of the most common type of cancer globally. Due to its high incidence rate, high risk of recurrence and progression, and frequent cystoscopy surveillance, BC contributes to major healthcare costs across the world. The goal of this prospective study was to evaluate the prognostic value of novel non-muscle invasive bladder cancer (NMIBC) biomarkers for predicting disease recurrence or progression after radical transurethral resection of bladder tumour (TURBT). The data obtained from this study may help physicians identify patients who are at greater risk of NMIBC recurrence or progression and require close supervision.

NCT ID: NCT06209606 Not yet recruiting - Multiple Myeloma Clinical Trials

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Start date: January 2024
Phase: Early Phase 1
Study type: Interventional

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease using BCMA to test progression.